Immunoglobulin Replacement Therapy Beneficial for Blood Cancers
By Elana Gotkine HealthDay Reporter
THURSDAY, June 27, 2024 -- Immunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), according to a study published online June 21 in Blood Advances.
Jacob D. Soumerai, M.D., from the Massachusetts General Hospital Cancer Center in Boston, and colleagues examined patterns of IgG testing and the effectiveness of IgRT in patients with CLL or NHL in a retrospective, longitudinal study. IgG testing, infections, and antimicrobial use were compared before with three, six, and 12 months after IgRT initiation. The study population included 17,192 patients: 3,960 with CLL and 13,232 with NHL.
Overall, 67 and 51.2 percent of the CLL and NHL cohorts had IgG testing and 6.5 and 4.7 percent received IgRT. The researchers found that the proportion of patients with hypogammaglobulinemia, odds of infections or severe infections, and associated antimicrobial use decreased significantly following IgRT initiation.
"As the treatment landscape evolves for patients with CLL and NHL, a critical need exists to develop guidelines and consensus on secondary immune deficiency monitoring and management," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Takeda Pharmaceuticals, which funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Improved Outcomes Seen With Ibrutinib in Chronic Lymphocytic Leukemia
FRIDAY, June 21, 2024 -- First-line ibrutinib is associated with better outcomes than chemoimmunotherapy among patients with chronic lymphocytic leukemia (CLL), according to a...
Algorithm From EHR Can ID Common Variable Immunodeficiency Disease
THURSDAY, May 2, 2024 -- A machine learning algorithm can identify patients with common variable immunodeficiency disease (CVID) from their electronic health records, according to...
Ending Specialized Follow-Up Feasible in Asymptomatic, Low-Risk Leukemia
THURSDAY, April 18, 2024 -- For select patients with asymptomatic, lower-risk chronic lymphocytic leukemia, ending specialized follow-up (sFU) is feasible and safe, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.